ArticleBreast cancer (Tokyo, Japan)2025
Stereotactic radiosurgery for HER2-positive breast cancer brain metastases: prognostic factors and the evolving role of anti-HER2 therapies.
Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to evaluate the clinical outcomes of SRS in patients with HER2-positive breast cancer brain metastases, focusing on survival, local control, and the influence of systemic therapies and clinical factors.
methodsA retrospective analysis was conducted on 60 patients with HER2-positive breast cancer and brain metastases treated with SRS. Patient demographics, tumor characteristics, treatment parameters, and follow-up data were collected.
resultsThe median follow-up was 21 months. 1-year, 2-year, and 3-year survival rates of 96%, 73%, and 50%, respectively. Factors associated with shorter OS included the presence of neurological deficits (p = 0.003), tumor diameter > 2.5 cm (p = 0.016), more than three brain metastases (p = 0.046), cumulative GTV volume greater than 2.63 cm
conclusionSRS combined with modern systemic therapies achieves favorable outcomes in HER2-positive breast cancer brain metastases, with improved survival and high local control rates. These findings highlight the need for personalized treatment strategies integrating local and systemic therapies to optimize intracranial disease management in this patient population.
Indexed as
Identifiers
40483635What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.